Actively Recruiting
Evaluation of the Efficacy of Biobran (Rice Bran Arabinoxylan) in Supporting Breast Cancer Chemotherapy
Led by China Medical University Hospital · Updated on 2026-03-31
96
Participants Needed
2
Research Sites
73 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study aims to evaluate the potential supportive effects of rice bran arabinoxylan compound (Biobran) in patients with breast cancer receiving paclitaxel and doxorubicin chemotherapy. The study will assess chemotherapy-related side effects, quality of life, tumor size, tumor antigens, and routine blood test parameters over 24 weeks of treatment.
CONDITIONS
Official Title
Evaluation of the Efficacy of Biobran (Rice Bran Arabinoxylan) in Supporting Breast Cancer Chemotherapy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Breast cancer stage I to III
- Female participants aged between 20 and 65 years
You will not qualify if you...
- Pregnant or breastfeeding women
- Breast cancer recurrence
- History of mental illness
- Autoimmune disease within the past 5 years
- Current use of plant or fungal polysaccharide health supplements
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
China Medical University Hospital
Taichung, Taiwan, 406040
Actively Recruiting
2
China Medical University
Taichung, Taiwan, 406040
Not Yet Recruiting
Research Team
C
Chong-Kuei Lii, PhD
CONTACT
Y
Yi-Chen Huang, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
SUPPORTIVE_CARE
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here